Literature DB >> 26434555

An Epitope-Specific Respiratory Syncytial Virus Vaccine Based on an Antibody Scaffold.

Xiaozhou Luo1, Tao Liu2, Ying Wang2, Haiqun Jia2, Yuhan Zhang2, Dawna Caballero2, Juanjuan Du2, Rongsheng E Wang2, Danling Wang2, Peter G Schultz3, Feng Wang4.   

Abstract

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children. We have generated an epitope-specific RSV vaccine by grafting a neutralizing epitope (F-epitope) in its native conformation into an immunoglobulin scaffold. The resulting antibody fusion exhibited strong binding affinity to Motavizumab, an RSV neutralizing antibody, and effectively induced potent neutralizing antibodies in mice. This work illustrates the potential of the immunoglobulin molecule as a scaffold to present conformationally constrained B-cell epitopes.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  RSV vaccine; antibodies; conformations; polypeptides; protein engineering

Mesh：

Substances：

Year:  2015        PMID： 26434555      PMCID： PMC4715490          DOI： 10.1002/anie.201507928

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


  23 in total

1.  Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.

Authors:  Rafael Ponce; Leslie Abad; Lakshmi Amaravadi; Thomas Gelzleichter; Elizabeth Gore; James Green; Shalini Gupta; Danuta Herzyk; Christopher Hurst; Inge A Ivens; Thomas Kawabata; Curtis Maier; Barbara Mounho; Bonita Rup; Gopi Shankar; Holly Smith; Peter Thomas; Dan Wierda
Journal:  Regul Toxicol Pharmacol       Date:  2009-04-02       Impact factor: 3.271

2.  Monoclonal antibodies protect against respiratory syncytial virus.

Authors:  G Taylor; E J Stott; M Bew; B F Fernie; P J Cote
Journal:  Lancet       Date:  1983-10-22       Impact factor: 79.321

3.  Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies.

Authors:  E E Walsh; J J Schlesinger; M W Brandriss
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

Review 4.  Respiratory syncytial virus infection.

Authors:  E A Simoes
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

5.  Amino acid variation within the fusion protein of respiratory syncytial virus subtype A and B strains during annual epidemics in South Africa.

Authors:  Elizabeth Agenbach; Caroline T Tiemessen; Marietjie Venter
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

6.  Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein.

Authors:  J A López; D Andreu; C Carreño; P Whyte; G Taylor; J A Melero
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891

7.  Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order.

Authors:  P L Collins; L E Dickens; A Buckler-White; R A Olmsted; M K Spriggs; E Camargo; K V Coelingh
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

8.  Risk of primary infection and reinfection with respiratory syncytial virus.

Authors:  W P Glezen; L H Taber; A L Frank; J A Kasel
Journal:  Am J Dis Child       Date:  1986-06

9.  Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.

Authors:  B R Murphy; E E Walsh
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

10.  Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.

Authors:  B R Murphy; G A Prince; E E Walsh; H W Kim; R H Parrott; V G Hemming; W J Rodriguez; R M Chanock
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948
View more
  5 in total

1.  Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.

Authors:  Jarrod J Mousa; Marion F Sauer; Alexander M Sevy; Jessica A Finn; John T Bates; Gabriela Alvarado; Hannah G King; Leah B Loerinc; Rachel H Fong; Benjamin J Doranz; Bruno E Correia; Oleksandr Kalyuzhniy; Xiaolin Wen; Theodore S Jardetzky; William R Schief; Melanie D Ohi; Jens Meiler; James E Crowe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

Review 2.  Antibody Epitopes of Pneumovirus Fusion Proteins.

Authors:  Jiachen Huang; Darren Diaz; Jarrod J Mousa
Journal:  Front Immunol       Date:  2019-11-29       Impact factor: 7.561

3.  A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV.

Authors:  Xiaolin Wen; Jennifer Pickens; Jarrod J Mousa; George P Leser; Robert A Lamb; James E Crowe; Theodore S Jardetzky
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

4.  Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein.

Authors:  Noushin Jaberolansar; Keith J Chappell; Daniel Watterson; Imogen M Bermingham; Istvan Toth; Paul R Young; Mariusz Skwarczynski
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

5.  Chimeric Pneumoviridae fusion proteins as immunogens to induce cross-neutralizing antibody responses.

Authors:  Eduardo Olmedillas; Olga Cano; Isidoro Martínez; Daniel Luque; María C Terrón; Jason S McLellan; José A Melero; Vicente Más
Journal:  EMBO Mol Med       Date:  2018-02       Impact factor: 12.137
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.